Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study von Yang, James Chih-Hsin, Lee, Dae Ho, Lee, Jong-Seok, Fan, Yun, de Marinis, Filippo, Okamoto, Isamu, Inoue, Takako, Rodriguez Cid, Jeronimo Rafael, Zhang, Li, Yang, Cheng-Ta, De La Mora Jimenez, Emmanuel, Zhou, Jianying, Perol, Maurice, Lee, Ki Hyeong, Vicente, David, Ichihara, Eiki, Riely, Gregory J., Luo, Yiwen, Bhagwati, Niyati Sanat, Lu, Shun

Volltext